M. Maiga

发表

Rapid in vivo detection of isoniazid-sensitive Mycobacterium tuberculosis by breath test

W. Bishai, Z. Sharp, V. Atudorei, 2014, Nature Communications.

Novel adjunctive therapies for the treatment of tuberculosis.

W. Bishai, E. Weinstein, A. Ordonez, 2014, Current molecular medicine.

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

W. Bishai, Shashank Gupta, S. Tyagi, 2013, American journal of respiratory and critical care medicine.

In Vitro and In Vivo Studies of a Rapid and Selective Breath Test for Tuberculosis Based upon Mycobacterial CO Dehydrogenase

W. Bishai, Z. Sharp, V. Atudorei, 2014, mBio.

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis

W. Bishai, F. Bougoudogo, M. Maiga, 2015, EBioMedicine.

Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams

A. Kubler, W. Bishai, K. Winglee, 2014, mBio.

Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.

W. Bishai, S. Franzblau, B. Wan, 2012, The Journal of antimicrobial chemotherapy.

Small Molecule-directed Immunotherapy against Recurrent Infection by Mycobacterium tuberculosis*

W. Bishai, D. Bhattacharya, L. Van Kaer, 2014, The Journal of Biological Chemistry.

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.

W. Bishai, M. Polis, N. Ammerman, 2013, The Journal of infectious diseases.

The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

W. Bishai, B. Andrade, A. Ordonez, 2016, JCI insight.

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis

W. Bishai, M. Maiga, B. Ahidjo, 2015, Antimicrobial Agents and Chemotherapy.